# Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.

> **NCT04107194** · PHASE3 · UNKNOWN · sponsor: **University of Bari** · enrollment: 362 (estimated)

## Conditions studied

- Helicobacter Pylori Infection
- Antibiotic Resistant Infection
- Antibiotic Resistant Strain

## Interventions

- **DRUG:** Pantoprazole 40mg
- **DRUG:** Amoxicillin 1000 MG
- **DRUG:** Clarithromycin 500mg
- **DRUG:** Metronidazole
- **DRUG:** Tetracycline 125 MG
- **DRUG:** Bismuth Subcitrate
- **DRUG:** Rifabutin 150 MG
- **DRUG:** Levofloxacin 500mg

## Key facts

- **NCT ID:** NCT04107194
- **Lead sponsor:** University of Bari
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-14
- **Primary completion:** 2021-02-14
- **Final completion:** 2022-04-14
- **Target enrollment:** 362 (ESTIMATED)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04107194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04107194, "Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04107194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*